Henry Finn, MD
Adult Reconstructive Orthopaedic Surgery · Chicago, ILNPI 1134225865
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $522,864 of the $523,215 with a category attached, or 99.9%. Zimmer Biomet accounts for 100.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $95,391 and has fallen 58.6% since, to $39,524 in 2025.
Across 36 payments — averaging $14,534 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$523K
- Smith+Nephew$141
- Hydrocision, Inc.$39
- Next Science LLC$20
- Si-bone, Inc.$14
What the payments were for
- Royalty or licence$522,864100%
- Food & beverage$3510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 32 | $523,001 |
| Smith+Nephew | 1 | $141 |
| Hydrocision, Inc. | 1 | $39 |
| Next Science LLC | 1 | $20 |
| Si-bone, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$523,215 in reported general payments places this provider in the 85th percentile of 67 adult reconstructive orthopaedic surgery providers in Illinois.
See all adult reconstructive orthopaedic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 51 | $3,317 |
| Cefadroxil | 68 | $2,419 |
| CeftriaxoneCeftriaxone Sodium | 15 | $2,349 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 67 | $771 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $567 |
| Levofloxacin | 15 | $415 |
| Amoxicillin | 156 | $389 |
| Cephalexin | 15 | $381 |
| Celecoxib | 11 | $282 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 16 | $221 |
| Methylprednisolone | 38 | $168 |
| Tramadol Hcl | 58 | $166 |
| Pregabalin | 18 | $110 |
| Clindamycin Hcl | 21 | $83 |
| Meloxicam | 46 | $80 |
Paid to pharmacies, not to this prescriber.
Other adult reconstructive orthopaedic surgery in Chicago
- Denis NamChicago$3.2M
- Craig della ValleChicago$2.4M
- Hany BedairChicago$1.1M
- Linda SuleimanChicago$898K
- Tad GerlingerChicago$642K
- Vasili KarasChicago$264K
- Brett LevineChicago$250K
- Sara WallaceChicago$148K
- Joshua JacobsChicago$72K
- William ThomasChicago$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.